Loading...
  • therapeutics
  • Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. (yahoo.com)
  • Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Moderna's Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. (yahoo.com)
  • And in the nascent field of mRNA therapeutics, researchers and investors are hoping to translate mRNA drugs from the lab to the medicine cabinet. (eurekalert.org)
  • Until now, the mRNA firm Moderna Therapeutics has been secretive about its technology, but now the company is opening up about its progress and challenges, reports an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society. (eurekalert.org)
  • Moderna
  • MRNA - Moderna, Inc. (yahoo.com)
  • Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately. (yahoo.com)
  • How Much Of Moderna, Inc. (NASDAQ:MRNA) Do Insiders Own? (yahoo.com)
  • If you want to know who really controls Moderna, Inc. (NASDAQ:MRNA), then you'll have to look at the makeup of its share registry. (yahoo.com)
  • Over the past five years, Moderna has spent an impressive $450 million on research into mRNA medicines and plans to spend another $500 million over the next five years, writes Assistant Editor Ryan Cross. (eurekalert.org)
  • Moderna and other firms are addressing these challenges by optimizing the mRNA sequences and developing drug delivery mechanisms. (eurekalert.org)
  • For example, Moderna scientists have made lipid nanoparticles that deliver a special sequence of mRNA that causes cancer cells, but not normal cells, to self-destruct. (eurekalert.org)
  • Despite the promise of mRNA medicines, skeptics are quick to point out that Moderna has only published human data from one study, an early-stage trial on an mRNA flu vaccine. (eurekalert.org)
  • Nucleotides
  • RNA editing alters nucleotides (the building blocks of DNA and RNA) within the mRNA to allow a single gene to create multiple mRNAs that are subject to different modes of regulation. (ucsd.edu)
  • Subgenomic mRNAs are created when transcription begins at the 3' end of the template strand (or 5' of the to-be-newly synthesized template) and begins to copy towards the 5' end of the template strand before "jumping" to the end of the template and copying the last nucleotides of the 5' end of the template, (finishing the 3' tail for the newly created strand). (wikipedia.org)
  • humans
  • Companies must still prove that mRNA medicines work in humans without side effects or complications, they say. (eurekalert.org)
  • structure
  • So when we discuss the structure of the mRNA, we will also naturally start with the head, following all the way to the tail. (everything2.com)
  • mRNA Cap 2´-O-Methyltransferase adds a methyl group at the 2´-O position of the first nucleotide adjacent to the cap structure at the 5´ end of the RNA. (neb.com)
  • Schematic representation of mRNA 5´ cap structure indicating the 7-methylguanosine, shown in yellow, and the 5´ end of the mRNA, shown in blue. (neb.com)
  • code
  • We're now finding how and why the mRNA code is being changed en route to the place of execution. (ucsd.edu)
  • alternative
  • Beaudoin JD and Perreault JP (2013) Exploring mRNA 3′‐UTR G‐quadruplexes: evidence of roles in both alternative polyadenylation and mRNA shortening. (els.net)
  • several
  • The cap is known as the 5' 7-methyl guanosine cap, and serves to identify the RNA as an mRNA (there are several other types of RNA, which do not concern us right now). (everything2.com)
  • Research
  • Moderna's Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Moderna's mRNA Research Platform with a focus on the Company's newest advances from its commitment to basic and applied sciences. (yahoo.com)
  • Role
  • Chatterjee S and Pal JK (2009) Role of 5′‐ and 3′‐untranslated regions of mRNAs in human diseases. (els.net)
  • ends
  • Andreassi C and Riccio A (2009) To localize or not to localize: mRNA fate is in 3′ UTR ends. (els.net)